<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TRIMETHOBENZAMIDE HYDROCHLORIDE - trimethobenzamide hydrochloride injection </strong><br>REMEDYREPACK INC. <br></p></div>
<h1>Trimethobenzamide Hydrochloride</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1>SPL UNCLASSIFIED</h1>
<p class="First"></p>
<p><span class="Italics">Injectable</span></p>
<p><span class="Italics">For Intramuscular use only.</span></p>
<p><span class="Italics">Not for use in pediatric patients.</span></p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"></p>
<p>Chemically, trimethobenzamide hydrochloride (HCl) is N-[<span class="Italics">p</span>-[2-(dimethylamino)ethoxy]benzyl]-3,4,5-trimethoxybenzamide monohydrochloride. It has a molecular weight of 424.93 and the following structural formula:</p>
<p><img alt="MM1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c1d3cc1f-f990-42b1-bc42-3551c1bfa12a&amp;name=MM1.jpg"></p>
<p>
 
</p>
<p></p>
<p>Each 2-mL single-dose vial contains 200 mg trimethobenzamide hydrochloride compounded with 1 mg sodium citrate and 0.4 mg citric acid as buffers and pH adjusted to approximately 5.0 with sodium hydroxide.</p>
<p>
 
</p>
<p></p>
<p>Each mL contains 100 mg trimethobenzamide hydrochloride compounded with 0.45% phenol as preservative, 0.5 mg sodium citrate and 0.2 mg citric acid as buffers and pH adjusted to approximately 5.0 with sodium hydroxide.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"></p>
<p>The mechanism of action of  trimethobenzamide hydrochloride as determined in animals is obscure, but may involve the chemoreceptor trigger zone (CTZ), an area in the medulla oblongata through which emetic impulses are conveyed to the <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> center; direct impulses to the <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> center apparently are not similarly inhibited. In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> induced by intragastric copper sulfate.</p>
<p>
 
</p>
<p></p>
<p>The pharmacokinetics of trimethobenzamide have been studied in healthy adult subjects. Following administration of 200 mg (100 mg/mL) trimethobenzamide hydrochloride IM injection, the time to reach maximum plasma concentration (T<span class="Sub">max</span>) was about half an hour, about 15 minutes longer for trimethobenzamide hydrochloride 300 mg oral capsule than an IM injection. A single dose of trimethobenzamide hydrochloride 300 mg oral capsule provided a plasma concentration profile of trimethobenzamide similar to trimethobenzamide hydrochloride 200 mg IM. The relative bioavailability of the capsule formulation compared to the solution is 100%. The mean elimination half-life of trimethobenzamide is 7 to 9 hours. Between 30 – 50% of a single dose in humans is excreted unchanged in the urine within 48 – 72 hours. The metabolic disposition of trimethobenzamide in humans is not known. Specifically, it is not known if active metabolites are generated in humans.</p>
<p>
 
</p>
<p></p>
<p><span>Age</span></p>
<p>The clearance of trimethobenzamide is not known in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.  However, it may be advisable to consider reduction in the dosing of trimethobenzamide in elderly patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> considering that a substantial amount of excretion and elimination of trimethobenzamide occurs via the kidney and that elderly patients may have various degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. (See <span class="Bold"><a href="#general">PRECAUTIONS: General</a></span> and <span class="Bold"><a href="#dosage">DOSAGE AND ADMINISTRATION</a>.</span>)</p>
<p>
 
</p>
<p></p>
<p><span>Gender</span></p>
<p>Systemic exposure to trimethobenzamide was similar between men (N=40) and women (N=28).</p>
<p>
 
</p>
<p></p>
<p><span>Race</span></p>
<p>Pharmacokinetics appeared to be similar for Caucasians (N=53) and African Americans (N=12).</p>
<p>
 
</p>
<p></p>
<p><span><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>The clearance of trimethobenzamide is not known in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.  However, it may be advisable to consider reduction in the dosing of trimethobenzamide in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> considering that a substantial amount of excretion and elimination of trimethobenzamide occurs via the kidney. (See <span class="Bold"><a href="#general">PRECAUTIONS: General</a></span> and <span class="Bold"><a href="#dosage">DOSAGE AND ADMINISTRATION</a>.</span>)</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS &amp; USAGE</h1>
<p class="First"></p>
<p>Trimethobenzamide hydrochloride is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">postoperative nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and for <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> associated with <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"></p>
<p>The injectable form of trimethobenzamide hydrochloride  is contraindicated in pediatric patients and in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to trimethobenzamide.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"></p>
<p>Trimethobenzamide hydrochloride may produce <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>. Patients should not operate motor vehicles or other dangerous machinery until their individual responses have been determined.</p>
<p>
 
</p>
<p></p>
<p>Trimethobenzamide hydrochloride was studied in reproduction experiments in rats and rabbits and no <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> was suggested. The only effects observed were an increased percentage of embryonic resorptions or stillborn pups in rats administered 20 mg and 100 mg/kg and increased resorptions in rabbits receiving 100 mg/kg. In each study these adverse effects were attributed to one or two dams. The relevance to humans is not known. Since there is no adequate experience in pregnant or lactating women who have received this drug, safety in pregnancy or in nursing mothers has not been established.</p>
<p>
 
</p>
<p></p>
<p>Concomitant use of alcohol with trimethobenzamide hydrochloride may result in an adverse drug interaction.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First"></p>
<p>During the course of acute febrile illness, encephalitides, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> and  <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>, especially in children and the elderly or debilitated, CNS reactions such as <span class="product-label-link" type="condition" conceptid="4313849" conceptname="Opisthotonus">opisthotonos</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> and <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span> have been reported with and without use of trimethobenzamide hydrochloride or other antiemetic agents. In such disorders caution should be exercised in administering trimethobenzamide hydrochloride, particularly to patients who have recently received other CNS-acting agents (phenothiazines, barbiturates, belladonna derivatives). Primary emphasis should be directed toward the restoration of body fluids and electrolyte balance, the relief of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and relief of the causative disease process. <span class="product-label-link" type="condition" conceptid="4266976" conceptname="Overhydration">Overhydration</span> should be avoided since it may result in <span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">cerebral edema</span>.</p>
<p>The antiemetic effects of trimethobenzamide hydrochloride may render diagnosis more difficult in such conditions as <span class="product-label-link" type="condition" conceptid="440448" conceptname="Appendicitis">appendicitis</span> and obscure signs of toxicity due to overdosage of other drugs.</p>
<p>
 
</p>
<p></p>
<p>A substantial route of elimination of unchanged trimethobenzamide is via the kidney. Dosage adjustment should be considered in patients with reduced renal function including some elderly patients. (See <span class="Bold"><a href="#clinical">CLINICAL PHARMACOLOGY</a></span> and <span class="Bold"><a href="#dosage">DOSAGE AND ADMINISTRATION</a>.</span>)</p>
<p>
 
</p>
<p></p>
<p>Clinical studies of trimethobenzamide hydrochloride did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. Although there are studies reported in the literature that include elderly patients &gt;65 years old with younger patients, it is not known if there are differences in efficacy or safety parameters for elderly and non-elderly patients treated with trimethobenzamide. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
<p>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. (See <span class="Bold"><a href="#clinical">CLINICAL PHARMACOLOGY</a></span> and <span class="Bold"><a href="#dosage">DOSAGE AND ADMINISTRATION</a>.</span>)</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"></p>
<p>There have been reports of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> and Parkinson-like symptoms. There have  been instances of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> reported following parenteral administration to surgical patients. There have been reports of <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasias</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurring of vision</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of mood, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span> and <span class="product-label-link" type="condition" conceptid="4313849" conceptname="Opisthotonus">opisthotonos</span>. If these occur, the administration of the drug should be discontinued. Allergic-type <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> have been observed; therefore, the drug should be discontinued at the first sign of sensitization. While these symptoms will usually disappear spontaneously, symptomatic treatment may be indicated in some cases.</p>
<p>For medical advice about adverse reactions contact your medical professional. To report SUSPECTED ADVERSE REACTIONS, contact JHP at 1-866-923-2547 or MEDWATCH at 1-800-FDA-1088 (1-800-332-1088) or http://www.fda.gov/medwatch/.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-9"></a><p></p>
<h1>DOSAGE &amp; ADMINISTRATION</h1>
<p class="First"></p>
<p>(See <span class="Bold"><a href="#warnings">WARNINGS</a></span> and <span class="Bold"><a href="#precautions">PRECAUTIONS</a></span>.)</p>
<p>Dosage should be adjusted according to the indication for therapy, severity of symptoms and the response of the patient<span class="Italics">.</span></p>
<p>
 
</p>
<p></p>
<p>Dose adjustments such as reducing the total dose administered at each dosing or increasing the dosing interval should be considered in elderly patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance ≤ 70 mL/min/1.73m<span class="Sup">2</span>). Final dose adjustment should be based upon integration of clinical efficacy and safety considerations. (See <span class="Bold"><a href="#clinical">CLINICAL PHARMACOLOGY</a></span> and <span class="Bold"><a href="#precautions">PRECAUTIONS</a>.</span>)</p>
<p>
 
</p>
<p></p>
<p>In subjects with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance ≤ 70 mL/min/1.73m<span class="Sup">2</span>), dose adjustment such as reducing the total dose administered at each dosing or increasing the dosing interval should be considered.  (See <span class="Bold"><a href="#clinical">CLINICAL PHARMACOLOGY</a></span> and <span class="Bold"><a href="#dosage">DOSAGE AND ADMINISTRATION</a>.</span>)</p>
<p>INJECTABLE, 100 mg/mL (Not for use in pediatric patients)</p>
<p> </p>
<p><span class="Italics">Usual Adult Dosage</span></p>
<p>2 mL (200 mg) t.i.d. or q.i.d. intramuscularly.</p>
<p><span class="Italics">NOTE:</span> The injectable form is intended for intramuscular administration only; it is not recommended for intravenous use.</p>
<p>Intramuscular administration may cause <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>, burning, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> and <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> at the site of injection. Such effects may be minimized by deep injection into the upper outer quadrant of the gluteal region, and by avoiding the escape of solution along the route.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="section-10"></a><p></p>
<h1>STORAGE AND HANDLING</h1>
<p class="First"></p>
<p>Store between 20° to 25°C (68° to 77°F).<br> (See USP Controlled Room Temperature.)</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"></p>
<p>Single Dose Vials, 2 mL, trays of 25<br>NDC 42023-143-25 100 mg/mL in 2 mL Single Dose Vials<br>Multi-Dose Vials, 20 mL<br>NDC 42023-142-01 100 mg/mL in 20 mL Multi-Dose Vials</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<h1>SPL UNCLASSIFIED</h1>
<p class="First"></p>
<p><span class="Bold">Rx Only</span><br>Prescribing Information as of February 2012.</p>
<p>Manufactured and Distributed by: <br>JHP Pharmaceuticals, LLC<br>Rochester, MI 48307</p>
<p>3003198</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION</h1>
<p class="First">
    DRUG: Trimethobenzamide Hydrochloride </p>
<p><br></p>
<p>GENERIC: trimethobenzamide hydrochloride</p>
<p><br></p>
<p>DOSAGE: INJECTION</p>
<p><br></p>
<p>ADMINSTRATION: INTRAMUSCULAR</p>
<p><br></p>
<p>NDC: 52125-805-52</p>
<p><br></p>
<p>ACTIVE INGREDIENT(S):</p>
<ul><li>trimethobenzamide hydrochloride 100mg in 1mL</li></ul>
<p><br></p>
<p>INACTIVE INGREDIENT(S):</p>
<ul>
<li>Citric Acid Monohydrate</li>
<li>Sodium Citrate</li>
</ul>
<p><br></p>
<p>PACKAGING: 2 mL in 1 VIAL, SINGLE-DOSE</p>
<p><br></p>
<p>OUTER PACKAGING: 25 VIAL in 1 TRAY</p>
<p><br></p>
<p><br></p>
<p><br></p>
<p><img alt="MM2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c1d3cc1f-f990-42b1-bc42-3551c1bfa12a&amp;name=MM2.jpg"></p>
<p><img alt="MM3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c1d3cc1f-f990-42b1-bc42-3551c1bfa12a&amp;name=MM3.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TRIMETHOBENZAMIDE HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">trimethobenzamide hydrochloride injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:52125-805(NDC:42023-143)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>trimethobenzamide hydrochloride</strong> (TRIMETHOBENZAMIDE) </td>
<td class="formItem">trimethobenzamide hydrochloride</td>
<td class="formItem">100 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Citric Acid Monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sodium Citrate</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:52125-805-52</td>
<td class="formItem">25  in 1 TRAY</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">2 mL in 1 VIAL, SINGLE-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA authorized generic</td>
<td class="formItem">NDA017530</td>
<td class="formItem">01/09/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>REMEDYREPACK INC. 
							(829572556)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 1/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>d37fbbc1-fe2a-490b-b01a-ead151f3e972</div>
<div>Set id: c1d3cc1f-f990-42b1-bc42-3551c1bfa12a</div>
<div>Version: 1</div>
<div>Effective Time: 20140109</div>
</div>
</div> <div class="DistributorName">REMEDYREPACK INC. </div></p>
</body></html>
